The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository
ConditionClonal Hematopoiesis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorVanderbilt-Ingram Cancer Center
About this trial
This study will investigate the association between clonal hematopoiesis and other conditions. Clonal hematopoiesis (CH) refers to the mutations in a person's stem cells which commonly affect people as they get older. These mutations have notably been linked to increased risk of certain cancers as well as increased risk of heart disease.
Eligibility criteria
Qualifiers
Patient greater than or equal to 18 years old at time of consent
Able to provide informed consent
Idiopathic cytopenia (ICUS) or idiopathic cytoses (elevated blood counts without disease or explanation); clonal cytopenia of undetermined significance (CCUS), clonal hematopoiesis of indeterminate potential (CHIP) or individuals at higher risk for clonal hematopoiesis (ex. patients with known diagnosis of solid tumors or cardiovascular disease)
Disqualifiers
Unable to provide consent
Diagnosis of active hematologic malignancy. For example, a diagnosis of CMML, AML, MDS, MPN; History of hematologic malignancy is NOT exclusionary if in complete remission (e.g. previous myeloma or lymphoma)
Trial design
Treatments tested in this trial
- Blood collection
- Saliva collection
- Bone marrow collection
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov